


Michael Mark Tarnow - South Orleans, MA | Intelius



























Sign In



We found Michael Mark Tarnow in South Orleans, MA


Michael Mark Tarnow

                                                                           Intelius found that Michael Mark Tarnow  is  a male between 70 and 80 years old from South Orleans, MA.  We have connected them to
                14 addresses,
                14 phones,
                and 2 relatives or associates.
         





Also Known As

Merle W Tarnow


Get Report Now

Age

Michael Mark Tarnow is in his 70s

Michael Has Lived In

South Orleans, MA
Mendham, NJ
New York, NY

Michael's Relatives

Noah Tarnow
Jessica Wilan







Michael Mark Tarnow



Zodiac SignTaurus



GenderMale



Professional Status
Several Senior Management Positions at Merck & Co. , Inc.



Get Report Now










Want to know more about Michael? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Michael, or use our people search engine to find others.
Get Background Check on Michael Mark Tarnow
Get a Criminal Check on Michael Mark Tarnow
Get a Public Record Report on Michael Mark Tarnow
Get a People Search Report on Michael Mark Tarnow


Michael Mark Tarnow's Contact Information
Known Cities Lived In
Find out where Michael Mark Tarnow has lived as well as Michael Mark Tarnow's phone numbers and email addresses.




Michael Mark Tarnow Has Lived in 4 States
Massachusetts Address for Michael Mark Tarnow


 P* B** 1*** 

South Orleans, MA


Has Lived In

South Orleans, MA
Mendham, NJ


Get Full Address Report










Phone Numbers Associated with Michael Mark Tarnow

(508) ***-**** - South Orleans, MA 
(617) ***-**** - Boston, MA 
(480) ***-**** - Scottsdale, AZ 


Get Full Phone Report



Email Addresses Associated with Michael Mark Tarnow

t*******1@***.com
m*****w@***.com
m*********w@***.net


Get Email Report




Michael Mark Tarnow's Education Information
Known Schools Attended
Learn about Michael Mark Tarnow's academic history.  Find out which schools Michael Mark Tarnow attended, the dates attended as well as the degrees Michael Mark Tarnow received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Michael Mark Tarnow Has Attended 3 Schools
Wayne State University Michael Mark Tarnow has a B.b.a. in Business Administration               
University of Illinois                                             
University of Illinois College of Law                                             


Michael Mark Tarnow's Professional Information
Information regarding Michael Mark Tarnow's professional history.  Find out previous places Michael Mark Tarnow has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Michael Mark Tarnow Has Worked at 5 Places
Company: Merck & Co. , Inc.
               Title: Several Senior Management Positions
Company: Xenon Pharmaceuticals Inc.
               Title: Director
Michael Mark Tarnow's Experience
Title: Several Senior Management Positions
               Company: Merck & Co. , Inc.
Job Details
               For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.
Title: Director
               Company: Xenon Pharmaceuticals Inc.
Job Details
               We focus on the development of novel medicines using our proprietary Extreme Genetics® platform. We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.
Additional Professional Information on Michael Mark Tarnow

 See Michael Mark Tarnow's LinkedIn Profile



Michael Mark Tarnow's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Michael Mark Tarnow


Michael Mark Tarnow's known Social Networks And Potential Email Matches

Find all of Michael Mark Tarnow's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Michael Tarnow
Username Matches

                  MichaelTarnow
                  TarnowMichael
                  Michael.Tarnow
                  Tarnow.Michael
                  Michael_Tarnow
                  Tarnow_Michael
                  Michael-Tarnow
                  Tarnow-Michael
                  MTarnow
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
M Tarnow







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











Michael M. Tarnow, Board Dir., Axcan Pharma Inc.














A publisher of Business Information since 1983   
  





 


   

Search Business Search Executive 
  Advanced Search 




  

Sign In  |  Hints 









Profile of Michael Tarnow 





 


Michael Tarnow

 

Board Dir. - Axcan Pharma Inc.

 


Michael Tarnow Email :
Please login 

 

Company Name : 
Axcan Pharma Inc. 

 

Company Website : 
www.axcan.com 

 

Company Address : 
22 Inverness Ctr. Pkwy., Birmingham, AL,United States, 


 


Michael Tarnow Profile :
Board Dir. - Axcan Pharma Inc. 

 


Michael Tarnow Biography :


Michael M. Tarnow, of Boston, Massachusetts, USA, has served on the Board since August 2000. He held various positions with Merck & Co., Inc. including President and Chief Executive Officer of Merck Frosst Canada from 1990 to 1994. From 1995 to 2000, he was President and Chief Executive Officer of Creative BioMolecules, Inc. a biotechnology corporation. Currently, he is Chairman of Entremed, Inc., a publicly traded company. He is also Chairman of the Board of Xenon Pharmaceuticals Incorporated and Chair of Ferghana Partners Group, two privately held companies. Mr. Tarnow serves as advisor to several early and mid-stage life sciences companies in North America and Europe. 

 


Michael Tarnow Colleagues :





Name 
Title 
Email 


Francois Painchaud 
Board Dir. 
Please login 


Rolland Dickson 
Board Dir. 
Please login 


David Mims 
Exec. VP, COO 
Please login 


Claude Sauriol 
Board Dir. 
Please login 


Leon Gosselin 
Chmn. 
Please login 













            Home  |  About Us  |  Product Information   |  Subscription  |  List Builder   |  Executive List   |  Email Lists   |  Contact Us  |  Site Map  |  Browse Directory    





 

� 2009, Walkers's Research - A publisher of Business Information since 1983, All Rights Reserved.





MICHAEL M  TARNOW - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











MICHAEL M  TARNOW
Check out list of companies and businesses related to MICHAEL M  TARNOW. Find out MICHAEL M  TARNOW address and contact details. View other people related to MICHAEL M  TARNOW - coworkers, colleagues, companions, etc.
Address:   

9640 MEDICAL CENTER DRIVE  ROCKVILLE 20850 MD




Companies related to MICHAEL M  TARNOW
CIKCompany NamePositionCompany Address0000895051CASI Pharmaceuticals, Inc.Director 9620 MEDICAL CENTER DR STE 300 ROCKVILLE 208500001582313Xenon Pharmaceuticals Inc.Director 200 - 3650 GILMORE WAY  BURNABY V5G 48W




MICHAEL M  TARNOW on the Web
Persons related to MICHAEL M  TARNOW - CASI Pharmaceuticals, Inc.NamePositionCityKenneth Walter  BairSVP, Research and Development ROCKVILLEThomas H  Bliss JrSVP, Bus. & Corp. Development ROCKVILLEMark R  BrayVice President, Research TORONTODONALD S  BROOKSDirector ROCKVILLEDONALD S  BROOKSDirector ROCKVILLEJames S  BurnsPresident and CEO ROCKVILLEJames S  BurnsPresident and CEO ROCKVILLEDWIGHT L  BUSHDirector ROCKVILLEDWIGHT L  BUSHDirector ROCKVILLEDWIGHT L  BUSHDirector ROCKVILLEDWIGHT L  BUSHDirector ROCKVILLEDWIGHT L  BUSHDirector ROCKVILLENEIL J  CAMPBELLPresident and COO ROCKVILLERONALD  CAPEDirector ROCKVILLERONALD  CAPEDirector ROCKVILLESARA B  CAPITELLIVP Fin & Principal Account Off ROCKVILLESARA B  CAPITELLIVP, Fin & Principal Accounting ROCKVILLESARA B  CAPITELLIVP, Finance & PAO ROCKVILLESARA B  CAPITELLIVP, Finance & PAO ROCKVILLESidor  CarolynROCKVILLECELGENE CORP /DE/10% Owner SUMMITMarc  CorradoV.P. Corporate Development ROCKVILLEMarc  CorradoVP Corporate Development ROCKVILLEHu  CynthiaROCKVILLEBush  DwightROCKVILLEWei-Wu  HeDirector ROCKVILLEWei-Wu  HeDirector ROCKVILLEWei-Wu  HeDirector ROCKVILLEWei-Wu  HeDirector ROCKVILLEWei-Wu  HeDirector ROCKVILLEHE XIE AI QI INVESTMENT MANAGEMENT (BEIJING) CO., LTD.BEIJINGChi Sing  HoCENTRALCynthia W.  HuCOO, General Counsel and Secy ROCKVILLECynthia W.  HuCOO, General Counsel & Sec ROCKVILLE,Cynthia W.  HuSee Remarks ROCKVILLECynthia W.  HuSee Remarks ROCKVILLEJames  HuangDirector ROCKVILLEJames  HuangDirector ROCKVILLEJames  HuangDirector ROCKVILLEJames  HuangDirector ROCKVILLECEVERA JENNIE  HUNTERDirector ROCKVILLECEVERA JENNIE  HUNTERDirector ROCKVILLECEVERA JENNIE  HUNTERDirector ROCKVILLECEVERA JENNIE  HUNTERDirector ROCKVILLECEVERA JENNIE  HUNTERDirector ROCKVILLEIDG-Accel China Growth Fund GP III Associates Ltd.K3IDG-Accel China Growth Fund III Associates L.P.K3IDG-Accel China Growth Fund III L.P.10% Owner K3IDG-Accel China III Investors L.P.K3Hunter-Cevera  JennieROCKVILLEUDO  KLEINSenior Vice President of R&D ROCKVILLEPETER S  KNIGHTDirector ROCKVILLEPETER S  KNIGHTDirector ROCKVILLEJianguang  LiBEIJINGDongliang  LinBEIJINGTak W.  MakDirector ROCKVILLETak W.  MakDirector ROCKVILLETak W.  MakDirector ROCKVILLETak W.  MakDirector ROCKVILLEBray  MarkROCKVILLERandall  MarkROCKVILLEMARK C M  RANDALLDirector ROCKVILLEMARK C M  RANDALLDirector ROCKVILLEMARK C M  RANDALLDirector ROCKVILLEKen  RenCEO and Director WEST DES MOINESKen Keyong  RenChief Executive Officer ROCKVILLEKen Keyong  RenChief Executive Officer ROCKVILLEKen Keyong  RenChief Executive Officer ROCKVILLEDANE R  SAGLIOChief Financial Officer ROCKVILLEDANE R  SAGLIOChief Financial Officer ROCKVILLEFranklin Cary  Salisbury jrDirector ROCKVILLECapitelli  SaraROCKVILLEHugo  ShongBEIJINGRAJESH C MD  SHROTRIYADirector IRVINERAJESH C MD  SHROTRIYADirector ROCKVILLECarolyn F  SidorCorp. VP and Chief Med. Ofcr ROCKVILLECarolyn F  SidorV.P. and Chief Medical Officer ROCKVILLESNOW MOON LTDROAD TOWNSPARKLE BYTE LTD10% Owner ROAD TOWNSpectrum Pharmaceuticals Cayman, L.P.HENDERSONSPECTRUM PHARMACEUTICALS INC10% Owner HENDERSONSPECTRUM PHARMACEUTICALS INCHENDERSONMak  TakROCKVILLEMICHAEL M  TARNOWDirector ROCKVILLEMICHAEL M  TARNOWDirector ROCKVILLEJINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP)  TIANJINTIANJINKathy  Wehmeir-DavisPrincipal Accounting Officer ROCKVILLEHe  Wei-WuROCKVILLECynthia  WongCOO, Gen Counsel and Secretary ROCKVILLECynthia  WongCOO & General Counsel ROCKVILLEAlex  WuDirector ROCKVILLEAlex  WuDirector ROCKVILLEAlex  WuDirector ROCKVILLEFei  YangGUANGZHOUSuyang  ZhangSHANGHAIQuan  ZhouDirector CENTRALAlexander A  ZukiwskiChief Medical Officer FLEMINGTONPersons related to MICHAEL M  TARNOW - Xenon Pharmaceuticals Inc.NamePositionCityMOHAMMAD  AZABDirector MOHAMMAD  AZABDirector BURNABYMOHAMMAD  AZABDirector BURNABYBIOTECHNOLOGY VALUE FUND II LPBIOTECHNOLOGY VALUE FUND L PBiotechnology Value Trading Fund OS LPGRAND CAYMANGary  BridgerEVP, Research & Development BURNABYBVF INC/ILBVF PARTNERS L P/IL10% Owner BVF Partners OS Ltd.GRAND CAYMANCHARLES J.  COHENVP, Biology BURNABYKAREN G.  CORRAINIGen. Counsel & Corp. Secretary BURNABYJAMES R.  EMPFIELDSVP, Drug Discovery BURNABYJohnston L  EvansDirector NEW YORKJohnston L  EvansDirector BURNABYSTEVEN  GANNONDirector BURNABYY. PAUL  GOLDBERGSVP, Clinical Development BURNABYDawn  GrahamDirector SAN FRANCISCOMichael R  HaydenDirector BURNABYMichael R  HaydenDirector BURNABYFRANK A  HOLLERDirector BURNABYMARK N  LAMPERTSAN FRANCISCOIAN  MORTIMERCFO & COO BURNABYAssociates, LLP  MX10% Owner CINCINNATIGARY  PATOUDirector WALTHAMGARY  PATOUDirector BURNABYGARY  PATOUDirector BURNABYSIMON N.  PIMSTONEPresident & CEO BURNABYSHERRINGTON  ROBINSVP Bus. & Corp. Development BURNABYRICHARD H  SCHELLERDirector EVAN A.  STEINDirector BURNABYMICHAEL M  TARNOWDirector ROCKVILLEMICHAEL M  TARNOWDirector BURNABYMICHAEL M  TARNOWDirector BURNABYRAYMOND  WINQUISTHead, Translational Research BURNABY












 








Michael Tarnow Boston, MA | Intelius




















 










50% off
75% off
80% off
      Special Offer
   

Hey, wait!


            Get the information you need with a Background Check for just $49.95 $24.95!
         

            Get the information you need with a People Search for just $3.95 $0.95!
         

            Get the information you need with a Phone Report for just $4.95 $0.95!
         



            Get the information you need with a Background Check for just $49.95 $24.95!
         

            Get the information you need with a People Search for just $3.95 $0.95!
         

            Get the information you need with a Phone Report for just $4.95 $0.95!
         




            Yes! I want this offer 


No, I'll pass on this offer 

×











Menu
Intelius Premier
Identity Protect
Help
Sign In









Browser Issue Detected
Cookies must be enabled in order for you to use services. However, it seems that cookies are disabled in your browser.
                  To use services, enable cookies by changing your browser options, then try again.

Show me how to enable cookies

After you enable cookies, please click here.



Search results for Michael  Tarnow in          Boston, MA
   


      We found 2 people that match
                     Michael  Tarnow in           Boston, MA
   


Filter






Narrow your results by:


Middle Initial:

All M.I.
M
S



Age:

All Ages
51-60
71-80



Previous City:

All Cities
Boston, MA
Brewster, MA
Charlotte, NC
Conesus, NY
Falls Church, VA
Houston, TX
Kenilworth, NJ
Mendham, NJ
New York, NY
Orleans, MA
Phoenix, AZ
Scottsdale, AZ
South Orange, NJ
South Orleans, MA



Filter








Narrow your results


All M.I.
M
S




All Ages
51-60
71-80




All Cities
Boston, MA
Brewster, MA
Charlotte, NC
Conesus, NY
Falls Church, VA
Houston, TX
Kenilworth, NJ
Mendham, NJ
New York, NY
Orleans, MA
Phoenix, AZ
Scottsdale, AZ
South Orange, NJ
South Orleans, MA



Filter



 ×









Narrow your results by:


Middle Initial:

All M.I.
M
S



Age:

All Ages
51-60
71-80



Previous City:

All Cities
Boston, MA
Brewster, MA
Charlotte, NC
Conesus, NY
Falls Church, VA
Houston, TX
Kenilworth, NJ
Mendham, NJ
New York, NY
Orleans, MA
Phoenix, AZ
Scottsdale, AZ
South Orange, NJ
South Orleans, MA



Filter








Narrow your results


All M.I.
M
S




All Ages
51-60
71-80




All Cities
Boston, MA
Brewster, MA
Charlotte, NC
Conesus, NY
Falls Church, VA
Houston, TX
Kenilworth, NJ
Mendham, NJ
New York, NY
Orleans, MA
Phoenix, AZ
Scottsdale, AZ
South Orange, NJ
South Orleans, MA



Filter



 



We found 2 people that match
                           Michael  Tarnow in           Boston, MA
   










1.


Michael Mark Tarnow
                                                   , age 73


Get more details





Has lived in
Has worked at
Has studied at
Related to
DOB
Phone
Address



Boston, MA
Mendham, NJ
Kenilworth, NJ
South Orange, NJ
View All


Merck & Co. , Inc.
Xenon Pharmaceuticals Inc.
Novopharm Biotech Inc.
Creative Biomolecules , Inc.
View All


Wayne State University
University Of Illinois
University Of Illinois College Of Law


Noah Tarnow
Jessica Wilan
















2.


Michael Scott Tarnow
                                                   , age 60


Get more details





Has lived in
Has worked at
Has studied at
Related to
DOB
Phone
Address



Boston, MA
Charlotte, NC
Falls Church, VA
Conesus, NY
View All


Papago Golf Course
Chart House
Brenner's Steakhouse
The Oceanaire Seafood Room
View All


Suny Geneseo
Baker High School
Baldwinsville High School


Francine Tarnow
Mike Tarnow
























1.



Michael Mark Tarnow
age 73
                        
Address History

                                                         Boston, MA;                                                          Mendham, NJ;                                                          Kenilworth, NJ;                                                          South Orange, NJ;                                                          New York, NY                                                                                    
                              ;
                                                            Brewster, MA;                                                             South Orleans, MA;                                                             Orleans, MA;                                                             Scottsdale, AZ                                                            
View All

Relatives

                                                         Noah Tarnow,                                                          Jessica Wilan                                                                                 
Worked at

                                                                                    Merck & Co. , Inc.;                                                          Xenon Pharmaceuticals Inc.;                                                          Novopharm Biotech Inc.;                                                          Creative Biomolecules , Inc.;                                                          Viventia Biotech Inc.                                                                                    
                              ;
                                                               Ceo Of Entremed                                                            
View All

Studied at

                                                                                    Wayne State University,                                                          University Of Illinois,                                                          University Of Illinois College Of Law                                                                                 
DOB
Available
Phone
Available


Get Report




2.



Michael Scott Tarnow
age 60
                        
Address History

                                                         Boston, MA;                                                          Charlotte, NC;                                                          Falls Church, VA;                                                          Conesus, NY;                                                          Scottsdale, AZ                                                                                    
                              ;
                                                            Houston, TX;                                                             Phoenix, AZ                                                            
View All

Relatives

                                                         Francine Tarnow,                                                          Mike Tarnow                                                                                 
Worked at

                                                                                    Papago Golf Course;                                                          Chart House;                                                          Brenner's Steakhouse;                                                          The Oceanaire Seafood Room;                                                          Darden Restaurants , Inc.                                                                                    
                              ;
                                                               The Capital Grille;                                                                Rare Hospitality International, Inc.                                                            
View All

Studied at

                                                                                    Suny Geneseo,                                                          Baker High School,                                                          Baldwinsville High School                                                                                 
DOB
Available
Phone
Available


Get Report









Not the right person? Search again:
Not the right person? Search again:



First Name



M.I.



Last Name required



City and/or State



Search














   Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.







What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
            prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.


×


 

 




















Michael Tarnow - Director Information (UK)















UK Corporate Information













COMPANIES
DIRECTORS












HomeCompany SearchDirector Search












HomeCompany SearchDirector SearchCompany by Zip Code










Michael Tarnow
191 Commonwealth Ave, Boston, Massachusetts, 02116, 


OVERVIEW - Michael TarnowLATEST NEWS









Michael Tarnow



Michael Tarnow was Born in May, 1944 (73 years old)  a resident of 191 Commonwealth Ave, Boston, Massachusetts, 02116,  (Usa) having Us nationality and currently holding positions as Director Michael Tarnow was appointed in over 1 companies and currently holding positions in over 0 companies listed below registered in United Kingdom (UK).













Mh Partners Limited



Address


                                    43-45 Dorset Street, , London, , W1U 7NA
                                



Standard Industry Classification (SIC)





Company Status

active




Appointment


RESIGNED
                                    Monday 19 May 2003 to Monday 31 December 2012
                                    
                                


Association
Michael Tarnow is associated with Mh Partners Limited since Monday 19 May 2003 as Director


View Full Profile of Mh Partners Limited >





Michael Tarnow - Latest News


Courtsey Carpet, Tile & Grout Cleaners LLCbuzzfile.com • Tuesday 06 June 2017Courtsey Carpet, Tile & Grout Cleaners is estimated to generate $88,795 in annual revenues, and employs approximately 1 people at this location. Where is Courtsey Carpet, Tile & Grout Cleaners located? Courtsey Carpet, Tile & Grout Cleaners is located at ...
XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Submission of Matters to a Vote of Security Holdersmarketexclusive.com • Friday 02 June 2017Item 5.07 Submission of Matters to a Vote of Security Holders. On June 1, 2017, Xenon Pharmaceuticals Inc. (the Company) held its 2017 Annual Meeting of Shareholders (the Annual Meeting).At the Annual Meeting, proxies and in-person shareholders ...
Northern Michigan Real Estate Consultants Incwww.chamberofcommerce.com • Tuesday 30 May 2017Northern Michigan Real Estate Consultants Inc has an annual sales volume of 501K - 999,999. .For more information contact Michael Tarnow, Co-Owner and Founder or go to *URL_MASKED* For maps and directions to Northern Michigan Real Estate Consultants Inc ...
Integrating iPad Technology in Learning Experiences:www.safaribooksonline.com • Monday 29 May 2017The introduction of user-friendly modern technology is significantly changing the traditional conduct of everyday life in all its manifestations, from health care and business to sport and all forms of entertainment, including social media. The education ...


View All News Articles >






Site2Corp - United Kingdom (UK)
Company Search
Director Search
Company By Zip Code
Insights
Company Statistics

Help
Frequently Asked Questions
Contact Us
Terms and Conditions
Privacy Policy

Looking for Companies In ?


India (IN)
United Kingdom (UK)




Copyright © 2016 Site2Corp






   Michael Tarnow | Xenon Pharmaceuticals Inc. | ZoomInfo.com




Michael M. Tarnow - The International Legal Honor Society of Phi Delta Phi 






























Print Page   |   Contact Us   |   Your Cart   |   Report Abuse   |   Sign In   |   Register











Search




Search »






HomeAbout 

About Phi Delta Phi©®

Coat of Arms & SealPDP Centennial HistoryNotable Phi Delta Phis

Why Join Phi Delta Phi©®?

Events And Awards

Officers of Phi Delta Phi©®

PDP Council & CourtPresidentChief JusticeExecutive DirectorInternational HistorianProvince Leadership

Directory

Member SearchActive Life Honor RollLost Members



Legal Honor Society

Student & Barrister Inns

Inn LocationsHow to Start a New Inn

Inn Forms & Documents

Forms & DocumentsRecruitment MaterialsInitiation Summary ReportOfficer Election ReportPDP ConstitutionPDP Initiation Ritual

En EspañolBalfour Scholarships

Scholarship Guidelines

Balfour Scholarship GuidelinesInternational Exchange Scholarship GuidelinesMinority Scholarship Guidelines

Scholarship Nomination FormScholarship ApplicationScholarship Winners

Grad & Inn of the Year Awards

Grad Guidelines & ApplicationGrad Notice of SelectionInn Guidelines & ApplicationGrad & Inn Award Winners

Mentorship ProgramCareer CenterMember BenefitsLinksDrug and Alcohol Policy Website User Guide 

Pre-Law Society

Pre-Law Halls

The Pre-Law SocietyHall LocationsHow To Start a New Hall

Hall Forms & Documents

Forms & DocumentsRecruitment MaterialsInitiation Summary ReportOfficer Election ReportPDP ConstitutionPre-Law Initiation Ritual

How I Compare Pre-Law Grad & Hall of the Year Awards

Pre-Law Grad Guidelines & ApplicationHall Guidelines & Application Pre-Law Grad & Hall Award Winners

Pre-Law to Law SchoolMentorship ProgramCareer CenterMember BenefitsLinksDrug and Alcohol PolicyWebsite User Guide 

Barrister Society

Barrister Inns & SocietyHow to Join a Barrister InnHow to Start a New Barrister InnMentorship ProgramVolunteer Speaker ProgramCareer CenterMember BenefitsWebsite User Guide 

Career CenterJoin 

Membership RequirementsInquire about Joining PDPNew Member RegistrationNew Member Initiation FeeCreate a New Inn/Hall










Michael M. Tarnow
	









		Michael Mark Tarnow
		
		Inns/Halls: University of Illinois- Langdell Inn	
		RAHWAY, New Jersey
		
















 






Sign In




Sign In securely
Haven't registered yet?


moreCalendar
The upcoming calendar is currently empty.Click here to view past events and photos »


moreLatest News
  6/13/2017John Giordano (O'Connor '02) Barrister Brief!  5/15/2017Vice President, Hon. John McClellan Marshall PDP Europe 


Online Surveys








 
 






The International Legal Honor Society of Phi Delta Phi
P. O. Box 11570
Fort Lauderdale, FL 33339
Ph: 202-223-6801 | Fax: 202-223-6808

                  Copyright 2015 The International Legal Honor Society of Phi Delta Phi©®



Association Management Software Powered by YourMembership  ::  Legal






XENE Michael M. Tarnow Insider Trades for Xenon Pharmaceuticals Inc.


































Bulletin






Investor Alert







London Markets Open in:



Asia Markets
Currencies
US Market Snapshot


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Xenon Pharmaceuticals Inc.

                  NASDAQ: XENE
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Xenon Pharmaceuticals Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


XENE

/quotes/zigman/38768128/composite


$
3.35




Change

+0.05
+1.52%

Volume
Volume 12,434
Quotes are delayed by 20 min








/quotes/zigman/38768128/composite
Previous close

$
			3.30
		


$
				3.35
			
Change

+0.05
+1.52%





Day low
Day high
$3.25
$3.41










52 week low
52 week high

            $2.85
        

            $9.95
        


















Insider Activity


Individual




Michael M. Tarnow



Mr. Michael M. Tarnow is Non-Executive Chairman at Ferghana Partners Group and Chairman at Xenon Pharmaceuticals, Inc. He is on the Board of Directors at Aptalis Pharma Canada, Inc., Creative Biomolecules, Inc., Massachusetts College of Art, Massachusetts College of Art Foundation, MediGene AG and The Food & Drug Law Institute. 
Mr. Tarnow was previously employed as Executive Chairman by EntreMed, Inc., President & Chief Executive Officer by Creative Biomolecules, Inc., President by Merck & Co., Inc., President & Chief Executive Officer by Merck Frosst Canada Ltd., Senior Executive Vice President by Merck-Medco Managed Care LLC, and an Advisor by PureTech Ventures LLC. He also served on the board at Caprion Pharmaceuticals, Inc., Caprion Proteomics, Inc. and Thallion Pharmaceuticals, Inc. 
He received his undergraduate degree from Wayne State University (Michigan) and a graduate degree from the University of Illinois College of Law. 



Transactions


Date
Shares
Transaction
Value





06/19/2017
1,028


 
Gift at $0 per share.


0


06/19/2017
1,028


 
Derivative/Non-derivative trans. at $3.51 per share.


3,608


01/26/2017
7,201


 
Gift at $0 per share.


0


12/12/2016
7,202


 
Gift at $0 per share.


0


12/12/2016
14,403


 
Derivative/Non-derivative trans. at $3.21 per share.


46,233


04/28/2016
1,543


 
Gift at $0 per share.


0


04/28/2016
1,543


 
Derivative/Non-derivative trans. at $3.35 per share.


5,169


11/02/2015
5,041


 
Gift at $0 per share.


0


11/02/2015
5,041


 
Derivative/Non-derivative trans. at $5.22 per share.


26,314


06/17/2015
1,543


 
Derivative/Non-derivative trans. at $4.95 per share.


7,637


01/08/2015
5,041


 
Derivative/Non-derivative trans. at $4.98 per share.


25,104


11/09/2014
16,718


 
Derivative/Non-derivative trans. at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Simon Neil Pimstone 
President, Chief Executive Officer & Director




Mr. Ian C. Mortimer 
Secretary, Chief Operating & Financial Officer




Dr. Y. Paul Goldberg 
Vice President-Clinical Development




Dr. Gary J. Bridger 
Executive Vice President-Research & Development




Mr. James R. Empfield 
Senior Vice President-Drug Discovery




Dr. Charles J. Cohen 
Vice President-Biological Sciences




Dr. Robin  Sherrington 
Senior VP-Business & Corporate Development




Ms. Dawn  Svoronos 
Director




Dr. Richard H. Scheller 
Director




Mr. Steven  Gannon 
Director




Dr. Michael R. Hayden 
Director




Mr. Michael M. Tarnow 
Chairman




Mr. Frank A. Holler 
Independent Director




Dr. Mohammad  Azab 
Independent Director




Dr. Gary  Patou 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




2:29 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
2:28aReckitt Benckiser profit rises on reduced costs
2:15aChinese regulator tells insurers to shape up
2:14aRandgold looks to get more out of Tongon mine
2:12aRyanair profit soars 55%; warns on overcapacity
2:10aSiemens and Bombardier in talks to form train JVs
2:09aVW asks EU to scrutinize German car makers
2:04aKKR close to announcing deal for WebMD
1:45aJulius Baer assets under management jump
1:44aRoyal Philips profit rises, begins share buybacks
1:44aRyanair profit rises 55%, beating expectations
1:34aHow OPEC committee’s coming meeting could make or break oil prices
1:32aOil prices steady with all eyes on OPEC meeting
1:13aJapan, Aussie stocks knocked by weak dollar, commodity prices
12:53aIMF cuts U.S. growth forecast for 2017, 2018
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15























































Xenon Pharmaceuticals Inc (XENE.O)  People | Reuters.com


























































X



Edition:

United States


















Africa
América Latina


عربي
Argentina


Brasil
Canada


中国
Deutschland


España
France


India
Italia


日本
México


РОССИЯ
United Kingdom

United States
















Xenon Pharmaceuticals Inc (XENE.O)










Related Topics: 
StocksStock ScreenerMarket DataHealthcareBiotechnology & Medical Research












                
                        Overview
                    



                
                        News
                    



                
                        Key Developments
                    



                
                        People
                    



                
                        Charts
                    



                
                        Financials
                    



                
                        Analysts
                    



                    
                            Research
                        



                    
                            Pulse
                        










				XENE.O on Consolidated Issue listed on NASDAQ Global Market


				3.35USD
21 Jul 2017





				    Change	(% chg)


		    
						    $0.05


					            (+1.52%)
					        






Prev Close

$3.30


Open

$3.35




Day's High

$3.40


Day's Low

$3.25




Volume

12,434


Avg. Vol

133,726




52-wk High

$9.95


52-wk Low

$2.85











					Summary





Name
Age
Since
Current Position




							Michael Tarnow

71


                                Chairman of the Board




							Ian Mortimer

39
2015

                                Chief Financial Officer, Chief Operating Officer




							James Empfield


2016

                                Senior Vice President - Drug Discovery




							Robin Sherrington

54
2012

                                Senior Vice President of Business and Corporate Development




							Charles Cohen

66
2008

                                Vice President - Biology




							Yigal Goldberg

55
2010

                                Vice President of Clinical Development




							Karen Corraini

60
2003

                                General Counsel and Corporate Secretary




							Simon Pimstone

47
2003

                                President, Chief Executive Officer, Director




							Mohammad Azab

59
2003

                                Director




							Steven Gannon

54
2015

                                Director




							Michael Hayden

65


                                Director




							Frank Holler

57


                                Director




							Gary Patou

57


                                Director




							Richard Scheller

64
2015

                                Director




							Dawn Svoronos

62
2016

                                Director



» Insider Trading





					Biographies





Name
Description




							Michael Tarnow


					
							Mr. Michael Tarnow is the Executive Chairman of the Board of Xenon Pharmaceuticals Inc. Since 1995, Mr. Tarnow has been an advisor to and member of the boards of directors of private and public healthcare and biotechnology companies in the U.S., Canada and Europe, including Axcan Pharma, Creative Biomolecules, Inc., Caprion Pharmaceuticals Inc. and MediGene AG. He served as chair of EntreMed, Inc. from February 2003 to February 2009, and served as Executive Chair of EntreMed, Inc. from February 2009 to January 2012. Mr. Tarnow holds a B.B.A. in Business Administration from Wayne State University and a J.D. from the University of Illinois, College of Law. Our Board believes that Mr. Tarnow is qualified to serve on our Board because of his senior management experience in the biopharmaceutical industry and his knowledge and perspective on the Corporation.




							Ian Mortimer


					
							Mr. Ian C. Mortimer, MBA., CPA., CMA. is a Chief Financial Officer, Chief Operating Officer of Xenon Pharmaceuticals Inc. Prior to joining us, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (“Tekmira”), a NASDAQ-listed biotechnology company focused on the development of RNA interference therapeutic drugs, from 2007 until October 2013. Mr. Mortimer was responsible for all aspects of Tekmira’s finance and capital markets activities and led Tekmira’s listing on NASDAQ in 2010. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.




							James Empfield


					
							Dr. James R. Empfield is Senior Vice President - Drug Discovery of the Company. Prior to joining Xenon, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Head of Research, Boston at Vertex Pharmaceuticals Inc. from 2011 until August 2015. At Vertex, Dr. Empfield was jointly responsible for the oversight of the operations and portfolio of the Boston research organization including the delivery of drug candidates from lead optimization projects into preclinical development. From 2006 to 2011, Dr. Empfield was Director, CNS Chemistry Department at AstraZeneca Pharmaceuticals LP and held various other positions at AstraZeneca from 1990 to 2006. Dr. Empfield has a Ph.D. in Chemistry from the University of Pennsylvania, a M.S. in Chemistry from Bucknell University and a B.S. in Chemistry from Lebanon Valley College.




							Robin Sherrington


					
							Mr. Robin Sherrington, Ph.D. is a Senior Vice President of Business & Corporate Development of Xenon Pharmaceuticals Inc. since February 2012, and has held various Senior Director positions in business development and other departments since joining us in March 2001. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. Prior to 1996 Dr. Sherrington was a post-doctoral fellow at University of Toronto, received his Ph.D. from the University College London, and his B.Sc. with honors from University of Reading.




							Charles Cohen


					
							Dr. Charles Cohen is a Vice President - Biology of Xenon Pharmaceuticals Inc. Prior to joining, Dr. Cohen worked at Vertex Pharmaceuticals as a Research Fellow II from 2004 to 2008. In this position he led biology teams targeting neuropathic pain and neuroinflammation. From 1986 to 2004, Dr. Cohen worked at Merck Research Laboratories (“MRL”). From 2000 to 2004, he served as Director of Neuroscience and was world-wide coordinator of MRL’s research on multiple sclerosis and neuroinflammation. From 1986 to 2000, Dr. Cohen was a member of the Ion Channel department, advancing to the level of Senior Investigator. Prior to MRL, Dr. Cohen served as a Senior Scientist at Bayer Pharmaceuticals. Dr. Cohen received his Ph.D. in Biophysics and Theoretical Biology from the University of Chicago and received post-doctoral training in the Department of Cardiology at the University of Chicago and the Department of Physiology at Yale University.




							Yigal Goldberg


					
							Yigal Paul Goldberg, M.B. ChB., Ph.D., is a Vice President of Clinical Development of Xenon Pharmaceuticals Inc. He as our Senior Director, Clinical Biology and Target Discovery from 2002 until February 2010, as our Senior Director, Scientific Programs from 2001 until 2002, and as our Director and Senior Scientist from 2000 until 2002. Since 2000 Dr. Goldberg has also worked at the University of British Columbia in the Department of Medical Genetics as a Medical Geneticist, Clinical Assistant Professor. Dr. Goldberg received his M.B. ChB. and Ph.D. from the University of Cape Town, and he obtained his specialization in clinical genetics, FRCPC from the University of British Columbia.




							Karen Corraini


					
							Ms. Karen Corraini J.D, General Counsel and Corporate Secretary of Xenon Pharmaceuticals Inc. and has held various positions since joining us in June 2001. Prior to joining us, Ms. Corraini practiced law at McCarthy Tétrault LLP from January 2000 until June 2001. From 1996 to 1999, Ms. Corraini was Managing Director and Chief Executive Officer of the Canadian Bacterial Diseases Network, an organization focused on the discovery and commercialization of microbiology-related research from a Canada-wide consortium of researchers. Prior to that, Ms. Corraini practiced law at the Canadian law firms of Goldsmith and Harshorne and Ferguson Gifford. Ms. Corraini is a member of the board of the Cystic Fibrosis Technology Initiative and of the British Columbia Chapter of the Association of Corporate Counsel. She also serves as a member of the Research Advisory Council for Cystic Fibrosis Canada. She received her Medical Laboratory Technology Degree from SAIT and Foothills Hospital, and a J.D. from the University of Victoria.




							Simon Pimstone


					
							Dr. Simon Pimstone M.B., ChB., Ph.D. is a President, Chief Executive Officer, Director of Xenon Pharmaceuticals Inc. Prior to founding our Corporation, Dr. Pimstone trained as a clinical research fellow with the Department of Medical Genetics at the University of British Columbia from 1994 until 1998, where he was responsible for managing a provincial lipid clinic outreach program providing lipid management to at risk patients in the Province of British Columbia. Dr. Pimstone holds an M.B. ChB. from the University of Cape Town, a FRCPC from the University of British Columbia, and a Ph.D. from the University of Amsterdam in cardiovascular genetics. Dr. Pimstone is a former director of Indel Therapeutics and a former director and chair of the Board of Directors of LifeSciences British Columbia, a non-profit industry association that supports the life science community, and a former director of the Providence Healthcare Research Trust, BC Advantage Life Sciences Fund, and BIOTECanada. Dr. Pimstone also serves as director of the private biotechnology company Enject Therapeutics Inc. since 2008 and a director of Eupraxia Pharmaceuticals Inc. since 2012, where he is also a member of the Compensation Committee. Our Board believes that Dr. Pimstone possesses specific attributes that qualify him to serve as a director, including his extensive executive leadership experience, many years of service on our Board and as our Chief Executive Officer and extensive knowledge of the Corporation and industry.




							Mohammad Azab


					
							Dr. Mohammad Azab is Director of Xenon Pharmaceuticals Inc. Dr. Azab has been the Chief Medical Officer of Astex Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and development of drugs in oncology and other areas, since July 2009 and has been President and Chief Medical Officer of Astex since January 2014. Prior to joining Astex, he was with Intradigm Corporation, a developer of RNAi therapeutics acquired by Silence Therapeutics PLC, where he served as President and Chief Executive Officer from July 2006 until November 2008 and as a director from July 2006 until January 2010. Prior to Intradigm Corporation, he served as Executive Vice President, of Research and Development and Chief Medical Officer for QLT Inc., and held several senior positions at AstraZeneca and Sanofi. Dr. Azab holds an M.B.A. from the Richard Ivey School of Business, University of Western Ontario, and an M.B. ChB. from Cairo University. He received post-graduate training and degrees in oncology research from the University of Paris-Sud and biostatistics from the University of Pierre et Marie Curie in Paris, France. Our Board believes Dr. Azab is qualified to serve on the Board because of his extensive senior management experience in our industry.




							Steven Gannon


					
							Mr. Steven R. Gannon is Director of Xenon Pharmaceuticals Inc. Mr. Gannon has an international reputation as a solutions-focused business executive with extensive financial experience in corporate growth initiatives including acquisitions, corporate alliances and partnerships within the pharmaceutical industry. His past executive experience includes serving as Chief Financial Officer, Senior Vice President of Finance, and Treasurer at Aptalis Pharma Inc. (formerly Axcan Pharma Inc.) where he led global finance operations, completed multiple acquisitions and financings leading to the eventual private sale of Aptalis in 2014. He previously served as Chief Financial Officer of Cryocath Technologies Inc., a medical device company that was sold to Medtronic in 2007; Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc.; and the Head of Finance and Administration of Mallinckrodt Medical Inc.'s Canadian operations. He currently serves as a non-executive director of Advanced Accelerator Applications S.A. Mr. Gannon received a Bachelor of Commerce in accounting and business systems from Concordia University and has been a chartered accountant since 1985. He has also completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in London, Ontario, Canada.




							Michael Hayden


					
							Dr. Michael R. Hayden is a Director of Xenon Pharmaceuticals Inc. Dr. Hayden previously served as our Chief Scientific Officer from January 1997 to September 2012. Since September 2012, Dr. Hayden has been Chief Scientific Officer and President of Global Research & Development of Teva Pharmaceutical Industries Ltd. (“Teva”). From January 2010 to November 2010, Dr. Hayden served on the board of directors of Med Biogene Inc., a publicly-traded life sciences company. Dr. Hayden has also been a professor of Medical Genetics at the University of British Columbia since August 1983, Director of the Center for Molecular Medicine and Therapeutics from 1992 to 2012 and Director of the Michael Smith Foundation for Health Research from 2011 to 2012. He is presently the Program Director of the Translational Laboratory in Genetic Medicine in Singapore. He received his Ph.D. and M.B. ChB. from the University of Cape Town and completed his post-doctoral fellowship and training at Harvard Medical School. Our Board believes Dr. Hayden is qualified to serve on our Board because of his scientific background, experience in the industry, and his extensive knowledge and perspective on the Corporation.




							Frank Holler


					
							Mr. Frank Holler is a Director of Xenon Pharmaceuticals Inc. Mr. Holler previously served as our President and Chief Executive Officer from February 1999 until June 2003. Since March 2004, Mr. Holler has been the Chief Executive Officer at BC Advantage Funds (VCC) Ltd., a venture capital firm and public company that invests in emerging life science, cleantech and information technology companies, where he has served as a director since March 2004 and as chair since January 2010. Since February 2014, Mr. Holler has served as a director of Sernova Corporation, a publicly-traded biotechnology company, where he is also a member of the audit and compensation committees. Mr. Holler has served on the board of directors of publicly-traded companies Protox Therapeutics (now Sophiris Bio) as chair and audit committee member from 2004 to 2011, Allon Therapeutics as director and chair of the Audit Committee from 2005 to 2013, and Aquinox Pharmaceuticals, Inc., a publicly-traded clinical stage pharmaceutical company, as director and chair of the Audit Committee from 2010 to 2013. He has also served as chair of the Audit Committee and chair of the Investment Committee for Genome BC, a large publicly funded research organization, from 2005 to 2011. In addition, Mr. Holler served as President and Chief Executive Officer of ID Biomedical Corporation, a publicly-traded biotechnology company, from 1991 to 1998 and was a founding director of Angiotech Pharmaceuticals, a publicly-traded biotechnology company, from 1992 to 1997. Mr. Holler was an Investment Banker with Wood Gundy Inc. (now CIBC World Markets) from 1984 to 1988 and Merrill Lynch Canada from 1988 to 1989. Mr. Holler holds a B.A. in Economics and an M.B.A. from the University of British Columbia.




							Gary Patou


					
							Dr. Gary Patou M.D. is a Director of Xenon Pharmaceuticals Inc. Dr. Patou has been a managing director of MPM Capital, a venture capital fund, since May 2005. He has served as Chief Medical Officer of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, since January 2009 and is senior medical advisor to Chiasma. Dr. Patou has previously served in various positions at private pharmaceutical companies, including as Chief Medical Officer for Peplin, Ltd. from June 2006 to April 2007, Chief Medical Officer at Cerimon Pharmaceuticals, Inc., from June 2005 to June 2006, and Chief Medical Officer at Oscient Pharmaceuticals, Inc. from February 2004 to April 2005. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds an M.B.B.S. from University College Hospital, London and a B.Sc. in immunology from University College London. Our Board believes that Dr. Patou’s qualifications to serve on our Board include his scientific background and extensive senior management experience in our industry.




							Richard Scheller


					
							Dr. Richard H. Scheller, Ph.D., is an Director of the Company. Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc. (“Genentech”) from January 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd. Since February 2015, Dr. Scheller has served as a member of the Board of Directors for ORIC Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Scheller holds a B.S. in Biochemistry from the University of Wisconsin and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Neurobiology at Columbia University. Our Board believes that Dr. Scheller’s qualifications to serve on our Board include his scientific background and extensive senior management experience in our industry.




							Dawn Svoronos


					
							Ms. Dawn Svoronos serves as Director of the Company. Ms. Svoronos retired in 2011 from Merck & Co. following a 23-year career in commercial positions of increasing seniority, most recently as President of Europe and Canada. In that role, Ms. Svoronos had full P&L responsibility for 30 European markets with annual sales of several billion dollars and an employee base of several thousand. Previously held positions with Merck include Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos sits on the board of Medivation Inc. and is chair of the board for Theratechnologies Inc. Ms. Svoronos received a B.A. in English and French Literature from Carleton University.











					Basic Compensation





Name
Fiscal Year Total




							Michael Tarnow

--




							Ian Mortimer

587,822




							James Empfield

--




							Robin Sherrington

385,031




							Charles Cohen

--




							Yigal Goldberg

437,149




							Karen Corraini

403,863




							Simon Pimstone

751,092




							Mohammad Azab

--




							Steven Gannon

--




							Michael Hayden

--




							Frank Holler

--




							Gary Patou

--




							Richard Scheller

--




							Dawn Svoronos

--



As Of 
30 Dec 2014





					Options Compensation





Name
Options
Value




							Michael Tarnow

0
0




							Ian Mortimer

0
0




							James Empfield

0
0




							Robin Sherrington

0
0




							Charles Cohen

0
0




							Yigal Goldberg

0
0




							Karen Corraini

0
0




							Simon Pimstone

0
0




							Mohammad Azab

0
0




							Steven Gannon

0
0




							Michael Hayden

0
0




							Frank Holler

0
0




							Gary Patou

0
0




							Richard Scheller

0
0




							Dawn Svoronos

0
0









					Insider Trading












Name
Shares Traded
Price


BVF PARTNERS L P
30,170
$4.00


BVF PARTNERS L P
46,795
$4.00


BVF PARTNERS L P
8,496
$4.00


BVF PARTNERS L P
2,884
$4.00


BVF PARTNERS L P
4,525
$4.00


BVF PARTNERS L P
854
$4.00


BVF PARTNERS L P
6,380
$4.00


BVF PARTNERS L P
1,362
$4.00


BVF PARTNERS L P
4,406
$4.00


BVF PARTNERS L P
357
$3.85


BVF PARTNERS L P
1,967
$3.85


Tarnow (Michael M)
1,028
$3.51


Tarnow (Michael M)
1,028
$0.00


BVF PARTNERS L P
1,271
$3.85


BVF PARTNERS L P
3,873
$3.85


BVF PARTNERS L P
6,097
$3.85


BVF PARTNERS L P
1,064
$3.85


BVF PARTNERS L P
1,160
$3.84


BVF PARTNERS L P
3,845
$3.84


BVF PARTNERS L P
6,774
$3.84


BVF PARTNERS L P
20,594
$3.85


BVF PARTNERS L P
73,749
$3.85


BVF PARTNERS L P
113,446
$3.85


BVF PARTNERS L P
53,260
$3.75


BVF PARTNERS L P
913
$3.75




» Full list on Insider Trading
















Related Topics: 
StocksStock ScreenerMarket DataHealthcareBiotechnology & Medical Research




















